CY1116548T1 - Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων - Google Patents

Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων

Info

Publication number
CY1116548T1
CY1116548T1 CY20141100010T CY141100010T CY1116548T1 CY 1116548 T1 CY1116548 T1 CY 1116548T1 CY 20141100010 T CY20141100010 T CY 20141100010T CY 141100010 T CY141100010 T CY 141100010T CY 1116548 T1 CY1116548 T1 CY 1116548T1
Authority
CY
Cyprus
Prior art keywords
disorders
liver
diphenylprop
derivatives
treatment
Prior art date
Application number
CY20141100010T
Other languages
English (en)
Inventor
Raphaël Darteil
Rémy Hanf
Dean Hum
Ingrid Dufour
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of CY1116548T1 publication Critical patent/CY1116548T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση παρέχει παράγωγα 1,3-διφαινυλπροπ-2-εν-1-όνης και φαρμακευτικές συνθέσεις που περιλαμβάνουν τα ίδια για την αγωγή ηπατικών διαταραχών, συγκεκριμένα εκείνων που απαιτούν τη μείωση του επιπέδου των βιοχημικών δεικτών όπως οι αμινοτρανσφεράσες στο πλάσμα. Τα παράγωγα 1,3-διφαινυλπροπ-2-εν-1-όνης Γενικού Τύπου (I) έχουν ηπατοπροστατευτικές ιδιότητες και μπορούν να χρησιμοποιηθούν σε μεθόδους για την αγωγή ηπατικών διαταραχών που εμπλέκουν την παθολογική ρήξη, φλεγμονή, εκφυλισμό και/ή πολλαπλασιασμό των ηπατικών κυττάρων, όπως η ηπατική ίνωση ή η λιπώδης νόσος του ήπατος.
CY20141100010T 2009-11-26 2014-01-07 Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων CY1116548T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306146 2009-11-26
EP10787363.0A EP2504005B1 (en) 2009-11-26 2010-11-26 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Publications (1)

Publication Number Publication Date
CY1116548T1 true CY1116548T1 (el) 2017-03-15

Family

ID=43587223

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100010T CY1116548T1 (el) 2009-11-26 2014-01-07 Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων
CY20181100759T CY1120444T1 (el) 2009-11-26 2018-07-20 Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181100759T CY1120444T1 (el) 2009-11-26 2018-07-20 Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων

Country Status (24)

Country Link
US (2) US8772342B2 (el)
EP (2) EP2504005B1 (el)
JP (4) JP5833016B2 (el)
KR (2) KR101865677B1 (el)
CN (2) CN104434891B (el)
AU (1) AU2010323066B2 (el)
BR (1) BR112012012815B8 (el)
CA (1) CA2781451C (el)
CY (2) CY1116548T1 (el)
DK (2) DK2641596T3 (el)
EA (1) EA020849B1 (el)
ES (2) ES2681794T3 (el)
HK (1) HK1175716A1 (el)
HU (1) HUE039731T2 (el)
IL (2) IL219914A (el)
LT (1) LT2641596T (el)
MX (1) MX2012006062A (el)
NZ (1) NZ600439A (el)
PL (2) PL2504005T3 (el)
PT (2) PT2641596T (el)
SI (2) SI2641596T1 (el)
TR (1) TR201810393T4 (el)
WO (1) WO2011064350A1 (el)
ZA (1) ZA201204658B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
PT2641596T (pt) * 2009-11-26 2018-07-31 Genfit Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
MY191100A (en) 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
US20150352065A1 (en) * 2013-01-18 2015-12-10 Genfit Methods of treatment of fibrosis and cancers
WO2014174524A1 (en) 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (el) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2015189401A1 (en) 2014-06-13 2015-12-17 Inventiva Ppar compounds for use in the treatment of fibrotic diseases.
PE20180027A1 (es) * 2015-02-06 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapia combinada
CN108138232B (zh) * 2015-09-14 2023-07-18 基恩菲特公司 用于诊断和评估非酒精性脂肪性肝炎的方法
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017143038A1 (en) * 2016-02-16 2017-08-24 Concert Pharmaceuticals, Inc. Deuterated gft-505
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
WO2017167935A1 (en) * 2016-03-31 2017-10-05 Genfit Methods of treatment of cholestatic diseases
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
FR3056909B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
AU2018208913A1 (en) * 2017-01-22 2019-09-12 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of GFT-505 and preparation method and use thereof
CN110418641A (zh) 2017-02-24 2019-11-05 基恩菲特公司 用于组合疗法的药物组合物
US11478440B2 (en) * 2017-04-18 2022-10-25 Genfit Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
CN111148742B (zh) 2017-11-30 2021-11-16 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途
US12030840B2 (en) 2018-08-03 2024-07-09 Genfit Elafibranor salts
SG11202103011YA (en) * 2018-10-11 2021-04-29 Basf As Aromatic compounds and pharmaceutical uses thereof
RU2702003C1 (ru) * 2019-03-18 2019-10-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Антистеатозное средство
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
CN110143890B (zh) * 2019-06-12 2020-12-22 天津科技大学 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
CN110143902B (zh) * 2019-06-12 2021-06-04 天津科技大学 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
CN115003653A (zh) 2020-02-10 2022-09-02 基恩菲特公司 艾拉菲诺的多晶型物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04202129A (ja) 1990-11-30 1992-07-22 Terumo Corp 肝障害治療薬
KR960703901A (ko) * 1993-08-19 1996-08-31 로즈 암스트롱 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
BR0111889A (pt) * 2000-06-20 2003-06-24 Atherogenics Inc 1,3-bis-(fenil-substituìdo)-2-propen-1-onas e seu uso para tratar distúrbios mediados por vcam-1
KR100567125B1 (ko) 2001-11-01 2006-03-31 주식회사 안지오랩 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
WO2005073184A1 (fr) 2004-01-08 2005-08-11 Genfit Composes derives de 1,3-diphenylprop-2-en-1-one, preparation et utilisations
JP4689331B2 (ja) 2005-04-19 2011-05-25 三菱電機株式会社 撮像装置
FR2902789A1 (fr) 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
DE102006062264A1 (de) 2006-12-22 2008-06-26 Joh. Barth & Sohn Gmbh & Co. Kg Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
PT2641596T (pt) 2009-11-26 2018-07-31 Genfit Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas

Also Published As

Publication number Publication date
EP2641596A1 (en) 2013-09-25
CA2781451C (en) 2019-04-16
PL2641596T3 (pl) 2018-10-31
ES2441665T3 (es) 2014-02-05
SI2504005T1 (sl) 2014-04-30
EP2504005A1 (en) 2012-10-03
IL219914A (en) 2015-10-29
ES2681794T3 (es) 2018-09-17
PT2641596T (pt) 2018-07-31
PL2504005T3 (pl) 2014-03-31
SI2641596T1 (sl) 2018-09-28
MX2012006062A (es) 2012-06-28
BR112012012815A8 (pt) 2018-02-27
KR20120101472A (ko) 2012-09-13
AU2010323066A1 (en) 2012-06-07
WO2011064350A1 (en) 2011-06-03
BR112012012815A2 (pt) 2017-12-12
US20140309165A1 (en) 2014-10-16
EP2504005B1 (en) 2013-11-06
US8895619B2 (en) 2014-11-25
CN104434891B (zh) 2018-03-30
US8772342B2 (en) 2014-07-08
KR20180031825A (ko) 2018-03-28
HUE039731T2 (hu) 2019-01-28
JP2020073468A (ja) 2020-05-14
JP6594400B2 (ja) 2019-10-23
EP2641596B1 (en) 2018-05-02
EA201290389A8 (ru) 2014-05-30
TR201810393T4 (tr) 2018-08-27
JP2018070642A (ja) 2018-05-10
AU2010323066B2 (en) 2014-12-11
CA2781451A1 (en) 2011-06-03
CN104434891A (zh) 2015-03-25
ZA201204658B (en) 2013-05-29
IL219914A0 (en) 2012-07-31
IL241791A0 (en) 2015-11-30
KR101865677B1 (ko) 2018-07-16
DK2641596T3 (en) 2018-08-06
HK1175716A1 (en) 2013-07-12
BR112012012815B8 (pt) 2021-05-25
BR112012012815B1 (pt) 2021-02-02
US20120252725A1 (en) 2012-10-04
EA020849B1 (ru) 2015-02-27
JP2016074670A (ja) 2016-05-12
LT2641596T (lt) 2018-08-10
KR101962209B1 (ko) 2019-03-26
DK2504005T3 (da) 2014-01-13
JP5833016B2 (ja) 2015-12-16
CY1120444T1 (el) 2019-07-10
PT2504005E (pt) 2014-01-10
EA201290389A1 (ru) 2013-01-30
NZ600439A (en) 2014-06-27
CN102647982B (zh) 2014-10-15
CN102647982A (zh) 2012-08-22
JP2013512228A (ja) 2013-04-11

Similar Documents

Publication Publication Date Title
CY1120444T1 (el) Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CO2018011064A2 (es) Inhibidores de bromodominios
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
HN2012001162A (es) Triazolopiridinas
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
CY1122006T1 (el) Παραγωγα προφαρμακου του (ε)-ν-μεθυλο-ν-((3-μεθυλοβενζοφουραν-2-υλο)μεθυλο)-3-(7-οξο-5,6,7,8-τετραϋδρο-1,8-ναφθυριδιν-3-υλο)ακρυλαμιδιου
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
TN2010000203A1 (en) Beta-lactamase inhibitors
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
DE602005026556D1 (de) Zusammensetzung zur proteasomhemmung
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
AR063027A1 (es) Derivados de sulfonamida
MX2019004375A (es) Inhibidores de bromodominios.
UY29965A1 (es) Derivados nuevos de indolizina, su proceso de prepración y las composiciones terapéuticas que los comprenden